Pub Date : 2023-02-27DOI: 10.32756/0869-5490-2023-1-30-35
R.E. Baisultanova, E. Osmanov, S.M. Akayeva, M. A. Karnaushkina
To evaluate the clinical features, course and outcomes of community-acquired pneumonia (CAP) in hospitalized patients with type 2 diabetes.
目的探讨2型糖尿病住院患者社区获得性肺炎(CAP)的临床特点、病程及转归。
{"title":"Impact of type 2 diabetes on the course and outcomes of community-acquired pneumonia in hospitalized patients","authors":"R.E. Baisultanova, E. Osmanov, S.M. Akayeva, M. A. Karnaushkina","doi":"10.32756/0869-5490-2023-1-30-35","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-1-30-35","url":null,"abstract":"To evaluate the clinical features, course and outcomes of community-acquired pneumonia (CAP) in hospitalized patients with type 2 diabetes.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"81 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90086728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-27DOI: 10.32756/0869-5490-2023-1-86-92
N. Ivashkina, O. Dorofeeva
At the beginning of 2020, a novel coronavirus designated as SARS-CoV-2 emerged in China and caused an outbreak of coronavirus disease 2019 (COVID-19). Pandemic has threatened global mental health via disruptive societal changes and neuropsychiatric sequelae including depression, anxiety and sleep disorders after SARS-CoV-2 infection. Virus is able to access CNS through blood circulation or neural pathway. Brain damage can be also due to hypoxia, hypercoagulation and endothelial dysfunction. The effects of psychological stressors and drug therapy may be also relevant for development of neuropsychiatric disorders after COVID-19. Women and patients with a history of mental disorders are more susceptible to neuropsychiatric disorders and frequently present with more severe complications. Affective, anxiety or psychotic disorders can persist for 6 months after recovery from COVID-19. These data highlight the need in drug therapy to treat depression and anxiety, to normalize sleep and to prevent the development of serious neuropsychiatric sequelae of infection.
{"title":"Anxiety, depression and sleep disorders after COVID-19","authors":"N. Ivashkina, O. Dorofeeva","doi":"10.32756/0869-5490-2023-1-86-92","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-1-86-92","url":null,"abstract":"At the beginning of 2020, a novel coronavirus designated as SARS-CoV-2 emerged in China and caused an outbreak of coronavirus disease 2019 (COVID-19). Pandemic has threatened global mental health via disruptive societal changes and neuropsychiatric sequelae including depression, anxiety and sleep disorders after SARS-CoV-2 infection. Virus is able to access CNS through blood circulation or neural pathway. Brain damage can be also due to hypoxia, hypercoagulation and endothelial dysfunction. The effects of psychological stressors and drug therapy may be also relevant for development of neuropsychiatric disorders after COVID-19. Women and patients with a history of mental disorders are more susceptible to neuropsychiatric disorders and frequently present with more severe complications. Affective, anxiety or psychotic disorders can persist for 6 months after recovery from COVID-19. These data highlight the need in drug therapy to treat depression and anxiety, to normalize sleep and to prevent the development of serious neuropsychiatric sequelae of infection.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85161388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-27DOI: 10.32756/0869-5490-2023-1-73-78
V. Logina, N. Bulanov, E. Kuznetsova, V. Rameev, A. Efimova, P. Novikov, S. Moiseev
Takayasu’s arteritis (TAK) is a systemic large vessel vasculitis that usually develops at young age in females and affects aorta and its branches (pulseless disease). Patients with TAK frequently present with renal artery stenosis associated with renovascular hypertension and ischemic nephropathy, whereas glomerular and interstitial kidney disease is very rare. As any other chronic inflammatory diseases, TAK can be complicated with AA-amyloidosis manifesting by progressive proteinuria, nephrotic syndrome and chronic renal failure. AA-amyloidosis in patients with TAK and other immune-mediated inflammatory disease justifies intensification of immunosuppressive and antiinflammatory therapy (e.g. using interleukin-6 inhibitors) that is essential to prevent progression of kidney amiloidosis.
{"title":"AA-amyloidosis as a rare cause of kidney disease in patient with Takayasu’s arteritis","authors":"V. Logina, N. Bulanov, E. Kuznetsova, V. Rameev, A. Efimova, P. Novikov, S. Moiseev","doi":"10.32756/0869-5490-2023-1-73-78","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-1-73-78","url":null,"abstract":"Takayasu’s arteritis (TAK) is a systemic large vessel vasculitis that usually develops at young age in females and affects aorta and its branches (pulseless disease). Patients with TAK frequently present with renal artery stenosis associated with renovascular hypertension and ischemic nephropathy, whereas glomerular and interstitial kidney disease is very rare. As any other chronic inflammatory diseases, TAK can be complicated with AA-amyloidosis manifesting by progressive proteinuria, nephrotic syndrome and chronic renal failure. AA-amyloidosis in patients with TAK and other immune-mediated inflammatory disease justifies intensification of immunosuppressive and antiinflammatory therapy (e.g. using interleukin-6 inhibitors) that is essential to prevent progression of kidney amiloidosis.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86869639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-27DOI: 10.32756/0869-5490-2023-1-79-85
Nephropathic cystinosis is a rare inherited disease characterized by cristallization of cystine in lyzosomes. Cystine accumulation is caused by the mutations in the CTNS gene encoding for cystinosine, a cystine transporter. Cystinosis commonly affects the kidneys leading to renal Fanconi sysnrome during the first year of life, followed by progressive kidney failure that necessitates initiation of renal replacement therapy in childhood or adolescence. In adulthood, patients also present with various systemic manifestations including photophobia, hypothyroidism, diabetes mellitus, hypogonadism (in males), myopathy, neurological disorders. Corneal crystal accumulation can be detected in all patients with cystinosis by slit-lamp examination. A diagnosis of cystinosis can be confirmed by measuring cystine levels in white blood cells and genetic testing. Early diagnosis is of vital importance given the availability of cysteamine, the specific cystinedepleting therapy, that delays the onset of end-stage renal disease and extrarenal manifestations.
{"title":"Nephropathic cystinosis: pathophysiology and effects of treatment","authors":"","doi":"10.32756/0869-5490-2023-1-79-85","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-1-79-85","url":null,"abstract":"Nephropathic cystinosis is a rare inherited disease characterized by cristallization of cystine in lyzosomes. Cystine accumulation is caused by the mutations in the CTNS gene encoding for cystinosine, a cystine transporter. Cystinosis commonly affects the kidneys leading to renal Fanconi sysnrome during the first year of life, followed by progressive kidney failure that necessitates initiation of renal replacement therapy in childhood or adolescence. In adulthood, patients also present with various systemic manifestations including photophobia, hypothyroidism, diabetes mellitus, hypogonadism (in males), myopathy, neurological disorders. Corneal crystal accumulation can be detected in all patients with cystinosis by slit-lamp examination. A diagnosis of cystinosis can be confirmed by measuring cystine levels in white blood cells and genetic testing. Early diagnosis is of vital importance given the availability of cysteamine, the specific cystinedepleting therapy, that delays the onset of end-stage renal disease and extrarenal manifestations.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76889598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-27DOI: 10.32756/0869-5490-2023-1-49-55
O. Dorofeeva, K. Zakharov, A. Grigoriev, V. Vasilyuk, A. Sidorova, A. Piven, N. Ivashkina, A. Globenko, A. Kapashin, O. Kovchan, M. Pasko
Comparative evaluation of the pharmacokinetics, safety profile and tolerability of Ranquilon® 1 mg tablets with a single administration under fasting and fed conditions among healthy male and female volunteers.
健康男性和女性志愿者在空腹和进食条件下单次给药兰奎龙1mg片的药代动力学、安全性和耐受性的比较评价
{"title":"Evaluation of Ranquilon® pharmacokinetics, safety profile and tolerability in healthy volunteers: a phase I clinical trial.","authors":"O. Dorofeeva, K. Zakharov, A. Grigoriev, V. Vasilyuk, A. Sidorova, A. Piven, N. Ivashkina, A. Globenko, A. Kapashin, O. Kovchan, M. Pasko","doi":"10.32756/0869-5490-2023-1-49-55","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-1-49-55","url":null,"abstract":"Comparative evaluation of the pharmacokinetics, safety profile and tolerability of Ranquilon® 1 mg tablets with a single administration under fasting and fed conditions among healthy male and female volunteers.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83128675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-27DOI: 10.32756/0869-5490-2023-1-42-48
M. Vatsik-Gorodetskaya, V. Tolkacheva, E. Cabello Montoya Flora, B. Sarlykov, L. Nazarov, S. Galochkin, N. Khutsishvili, M. Diane, Z. Kobalava
To evaluate the clinical and prognostic significance of a comprehensive assessment of the hydration status in patients with acute decompensation of chronic heart failure (ADCHF).
目的探讨慢性心力衰竭急性失代偿(ADCHF)患者水合状态综合评估的临床及预后意义。
{"title":"Comprehensive assessment of the hydration status in patients with acute decompensated heart failure: clinical associations and prognostic significance","authors":"M. Vatsik-Gorodetskaya, V. Tolkacheva, E. Cabello Montoya Flora, B. Sarlykov, L. Nazarov, S. Galochkin, N. Khutsishvili, M. Diane, Z. Kobalava","doi":"10.32756/0869-5490-2023-1-42-48","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-1-42-48","url":null,"abstract":"To evaluate the clinical and prognostic significance of a comprehensive assessment of the hydration status in patients with acute decompensation of chronic heart failure (ADCHF).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82998990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-27DOI: 10.32756/0869-5490-2023-1-64-72
M. Litvinova, N. Bulanov, P. Novikov, N. Vlasenko, E. Filatova, K. Kurginyan, A. Skvortsov, S. Moiseev
Patients with ANCA-associated vasculitides usually present with similar clinical manifestations (fever, joint pain, lung and kidney diseases, purpura, etc.). However, signs of granulomatosis inflammation of the upper and lower respiratory tract and/or orbit allow to differentiate granulomatosis with polyangiitis (GPA) from microscopic polyangiitis (MPA). Circulating ANCAs are the key laboratory sign of ANCA-associated vasculitis, although they can be negative in a proportion of patients and can be found in patients with other diseases. GPA is usually associated with ANCAs againts proteinase-3, whereas ANCAs against myeloperoxidase are more common in patients with MPA. The authors present two patients with ANCA-associated vasculitides and discuss the common clinical features and differences between GPA and MPA and new classification criteria.
{"title":"Granulomatosis with polyangiitis and microscopic polyangiitis: common features and differences","authors":"M. Litvinova, N. Bulanov, P. Novikov, N. Vlasenko, E. Filatova, K. Kurginyan, A. Skvortsov, S. Moiseev","doi":"10.32756/0869-5490-2023-1-64-72","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-1-64-72","url":null,"abstract":"Patients with ANCA-associated vasculitides usually present with similar clinical manifestations (fever, joint pain, lung and kidney diseases, purpura, etc.). However, signs of granulomatosis inflammation of the upper and lower respiratory tract and/or orbit allow to differentiate granulomatosis with polyangiitis (GPA) from microscopic polyangiitis (MPA). Circulating ANCAs are the key laboratory sign of ANCA-associated vasculitis, although they can be negative in a proportion of patients and can be found in patients with other diseases. GPA is usually associated with ANCAs againts proteinase-3, whereas ANCAs against myeloperoxidase are more common in patients with MPA. The authors present two patients with ANCA-associated vasculitides and discuss the common clinical features and differences between GPA and MPA and new classification criteria.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"24 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74168076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-27DOI: 10.32756/0869-5490-2023-1-21-29
To evaluate the occurrence and clinical features of interstitial lung disease (ILD) in a cohort of Russian patients with primary biliary cholangitis (PBC).
评价俄罗斯原发性胆道胆管炎(PBC)患者间质性肺疾病(ILD)的发生和临床特征。
{"title":"Patterns of interstitial lung disease in primary biliary cholangitis","authors":"","doi":"10.32756/0869-5490-2023-1-21-29","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-1-21-29","url":null,"abstract":"To evaluate the occurrence and clinical features of interstitial lung disease (ILD) in a cohort of Russian patients with primary biliary cholangitis (PBC).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"72 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74390208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-27DOI: 10.32756/0869-5490-2023-1-56-63
V. Khirmanov
The author reviews the pharmacological properties and clinical trials of vericiguate, a stimulant of soluble guanylate cyclase, that is intended for use in patients with chronic heart failure. The new medicine alleviates unfavorable effects of endothelial dysfunction and other disorders associated with a deficiency of bioavailable nitric oxide and suppressed activity of soluble guanylate cyclase. The efficacy of vericiguate in chronic heart failure with a reduced ejection fraction was established in clinical trials SOCRATES-REDUCED and VICTORIA.
{"title":"Vericiguate: a new treatment for chronic heart failure","authors":"V. Khirmanov","doi":"10.32756/0869-5490-2023-1-56-63","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-1-56-63","url":null,"abstract":"The author reviews the pharmacological properties and clinical trials of vericiguate, a stimulant of soluble guanylate cyclase, that is intended for use in patients with chronic heart failure. The new medicine alleviates unfavorable effects of endothelial dysfunction and other disorders associated with a deficiency of bioavailable nitric oxide and suppressed activity of soluble guanylate cyclase. The efficacy of vericiguate in chronic heart failure with a reduced ejection fraction was established in clinical trials SOCRATES-REDUCED and VICTORIA.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"110 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72882966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-27DOI: 10.32756/0869-5490-2023-1-36-41
S. Moiseev, E. Tao, A. Moiseev, E. Mershina, V. Sholomova, N. Bulanov, E. Pavlikova, V. Fomin
To evaluate the occurence of cardiac phenotype imitating hypertrophic cardiomyopathy (HCMP) in adult patients with Fabry disease.
目的探讨成人法布里病患者心肌表型模拟肥厚性心肌病(HCMP)的发生情况。
{"title":"Fabry disease as a cause of hypertrophic cardiomyopathy","authors":"S. Moiseev, E. Tao, A. Moiseev, E. Mershina, V. Sholomova, N. Bulanov, E. Pavlikova, V. Fomin","doi":"10.32756/0869-5490-2023-1-36-41","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-1-36-41","url":null,"abstract":"To evaluate the occurence of cardiac phenotype imitating hypertrophic cardiomyopathy (HCMP) in adult patients with Fabry disease.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86632623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：